| Original language | English |
|---|---|
| Pages (from-to) | 819-820 |
| Number of pages | 2 |
| Journal | Journal of the American College of Cardiology |
| Volume | 72 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 14 Aug 2018 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the American College of Cardiology, Vol. 72, No. 7, 14.08.2018, p. 819-820.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Are All Benefits and Harms Equal?
AU - Saeed, Anum
AU - Virani, Salim S.
AU - Ballantyne, Christie M.
AU - Taylor, Addison A.
AU - Nambi, Vijay
N1 - Funding Information: Please note: Dr. Virani has received research grants from the American Heart Association, American Diabetes Association, and U.S. Department of Veterans Affairs; has received honoraria from the American College of Cardiology and National Lipid Association; and has served on the steering committee of the PALM Registry at Duke University. Drs. Ballantyne and Nambi have a provisional patent (patent no. 61721475) filed along with Baylor College of Medicine and Roche for the use of biomarkers in prediction of heart failure. Dr. Ballantyne has received grant/research support from Abbott Diagnostic, Akcea, Amarin, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, National Institutes of Health, American Heart Association, and American Diabetes Association; and has served as a consultant to Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Eli Lilly, Esperion, Gilead, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. Dr. Taylor has received grant/contract financial support from the National Institutes of Health; has served on the advisory board of Relypsa Medical; and has served as co-investigator for Kowa Research Institute (Pemafibrate to reduce cardiovascular outcomes in reducing triglycerides in patients with diabetes). Dr. Nambi has received support from a grant from the U.S. Department of Veterans Affairs titled Biomarker guided therapies in Stage A/B Heart Failure; has received honorarium from Siemens for assisting with event adjudication in a study; and has served as site principal investigator for a study sponsored by Merck. Dr. Saeed has reported that he has no relationships relevant to the contents of this paper to disclose.
PY - 2018/8/14
Y1 - 2018/8/14
UR - http://www.scopus.com/inward/record.url?scp=85050681502&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.05.055
DO - 10.1016/j.jacc.2018.05.055
M3 - Letter
C2 - 30092962
AN - SCOPUS:85050681502
SN - 0735-1097
VL - 72
SP - 819
EP - 820
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 7
ER -